Key facts
- RxLightning’s last known valuation is $52.5M (May 2023).
- It has raised $20.5M across 3 recorded rounds; the latest was Early Stage VC ($17.5M) in May 2023.
- RxLightning has filed 4 Form Ds with the SEC since 2021, most recently Jun 2023 ($17.5M sold to 12 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 3 rounds
- ·Watchlist + deal alerts for RxLightning
Funding rounds
3 roundsAbout RxLightning
Developer of a specialty prescription management platform designed to digitize, automate, and streamline the enrollment process. The company offers a platform that includes digital enrollment forms, benefits verification, prior authorization automation, consent collection, patient assistance program integration, real-time onboarding visibility, and progress tracking, enabling healthcare providers to reduce paperwork, streamline communication, and accelerate the speed of therapy for patients.
- Sector
- Healthcare
- HQ
- New Albany, IN, United States
- Founded
- 2020
- Employees
- 15
- Website
- rxlightning.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
RxLightning doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RxLightning shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RxLightning in its N-PORT filings yet. We sweep new filings monthly.